Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07316608 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT07316608: Completed Phase 1 study, sponsored by AstraZeneca.
NCT07316608 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 44 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07316608, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative bioavailability) in healthy adults.
Primary Outcome
To evaluate the relative bioavailability between the FCDP test formulation 1 and the STPs of laroprovstat and rosuvastatin across the planned rosuvastatin dose range, Dose 1 (Cohort 1) to Dose 2 (Cohort 2)
Interventions
- DRUG Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1
- DRUG Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1
- DRUG Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2
- DRUG Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2
- DRUG Laroprovstat Dose X STP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2026-03-16 |
| Est. Completion | 2026-06-05 |
| Phase | Phase 1 |
What the finished NCT07316608 record still lists
NCT07316608 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (27% lower).
The record links to 0 conditions, and to 5 interventions - of which Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1 is the first listed.
NCT07316608 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07316608 about?
NCT07316608 is a clinical study titled "A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults". The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative bioavailability) in healthy adults.
What is the current status of trial NCT07316608?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2026-03-16. Estimated completion is 2026-06-05.
What interventions are being tested in trial NCT07316608?
The interventions under investigation include: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1 (DRUG), Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1 (DRUG), Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2 (DRUG), Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2 (DRUG), Laroprovstat Dose X STP (DRUG).
Who is sponsoring clinical trial NCT07316608?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07316608's enrollment target sits among peer trials
44 1086th of 2000 higher than 901 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI